Predictive Health Diagnostics Company, Inc., which develops, manufactures, and distributes specialty diagnostic tests in combination with science, technology, and proprietary analytics, detecting diseases with significant unmet medical needs, has recently announced its acquisition of MUSE Microscopy. It's a valued intellectual property portfolio developed jointly at Lawrence Livermore National Laboratory and the Davis University of California.  

MUSE Microscopy is one of the leading histology-free digital microscopes that has provided the most significant advances in the industry for over 100 years. With this strategic acquisition, PHDC's MUSE platform will be the foundation that supports the Company's future development of imaging-based diagnostics. 

PHDC Chief Executive Officer Matthew Nuñez said, "The MUSE microscope is a truly groundbreaking instrument that is driving a paradigm shift in data collection methodology within the field of diagnostic medicine."   

Moreover, he also added, "This optics-enabled microscopy method is revolutionizing medical testing by delivering non-subjective empirically-derived diagnoses for a range of diseases. With our wholly-owned MUSE IP portfolio, we will manufacture and sell the instruments while at the same time building a master imaging repository that will be the foundation of our imaging diagnostics development platform. This acquisition adds imaging diagnostics to our existing molecular diagnostics platform, both driven by advanced AI algorithms. Our comprehensive and unmatched diagnostics development platform pushes PHDC to the leading edge of specialty diagnostics." 

The MUSE Microscope uses short-wavelength UV light, which penetrates only microns-deep into tissues, eliminating the need for precision-cut, even slides, and thin specimens. Additionally, short-wavelength UV light excites many fluorescent dyes simultaneously for snapshot color images. The result is stunningly detailed histology-free images of unparalleled resolution, structure, and depth.